Olanzapine increases severity of pulmonary Staphylococcus aureus infection in mice through reduced neutrophil recruitment and activation

For millions of people living with schizophrenia and related conditions, a class of medications known as second-generation antipsychotics offers a vital lifeline. These drugs help manage severe symptoms, allowing individuals to navigate daily life with greater stability. However, medical records have long hinted at a troubling side effect: people taking these medications appear to die from pneumonia more often than those who are not. Pneumonia is a serious infection of the lungs where bacteria invade the air sacs, and the body's immune system must fight back fiercely to clear them. One of the most important soldiers in this defense is a type of white blood cell called a neutrophil. These cells rush to the site of infection, engulf the invading bacteria, and release chemicals to destroy them. When this recruitment fails, the infection can spread from the lungs into the bloodstream, becoming a life-threatening crisis. The question that has lingered in the medical community is whether the medications themselves are somehow weakening this natural defense system, or if the higher death rates are simply due to other factors associated with the illness.

Researchers at King's College London and University College London set out to answer this question by looking directly at how a specific antipsychotic drug, olanzapine, affects the body's ability to fight a common and dangerous lung bacteria called Staphylococcus aureus. They began by testing human blood in a laboratory setting, mixing it with the bacteria and the drug to see if the immune cells changed their behavior. They found that while the drug did not stop the production of these white blood cells, it did seem to quiet their alarm systems. The cells were slower to arrive at the scene and less aggressive in their attack. However, when the researchers tested this in healthy mice that had never had lung damage, the drug did not seem to make the infection worse. The mice were still able to clear the bacteria effectively, even with the drug in their system. This suggested that the drug alone might not be the sole cause of the increased risk seen in patients.

The story changed when the researchers introduced a second factor: pre-existing lung injury. In the real world, many people who take antipsychotics also suffer from chronic respiratory conditions like chronic obstructive pulmonary disease, often linked to smoking. To mimic this, the team created a "two-hit" model in mice. First, they damaged the animals' lungs with a substance that causes inflammation and injury, similar to what happens in chronic lung disease. Then, they treated these injured mice with olanzapine before infecting them with the bacteria. The result was stark. In mice with damaged lungs, the drug prevented the immune system from mounting a proper defense. The neutrophils failed to gather in sufficient numbers, and the bacteria were not cleared from the lungs. Instead of staying contained, the infection spread to the kidneys and the spleen, and the mice developed a severe, body-wide inflammatory response. The drug had essentially disarmed the immune system at the very moment it was needed most, but only in lungs that were already compromised.

To see if this matched what happens in humans, the team analyzed a massive database of drug-related deaths in the United Kingdom. They looked at people who had died while taking olanzapine and checked their medical histories for signs of lung disease, using prescriptions for inhaled corticosteroids as a marker for such conditions. They found that patients who were taking olanzapine and also had a prescription for these inhaled steroids were significantly more likely to die from pneumonia than those taking olanzapine alone. This statistical link supported the animal findings: the combination of the antipsychotic drug and the underlying lung vulnerability created a dangerous perfect storm. The researchers also tested what happened when they added an inhaled steroid directly to the mice with damaged lungs. While the steroid did not make the immune suppression worse on its own, it did delay the clearing of bacteria when combined with the antipsychotic drug, further confirming that the two treatments together impair the body's ability to fight off the infection.

The study concludes that olanzapine does not simply stop the body from making immune cells, but rather dulls their ability to respond quickly and effectively to a bacterial invasion. In a healthy person with strong lungs, this dampening effect might be manageable. But for a patient with chronic lung damage, where the immune system is already struggling to function, the additional suppression caused by the drug can be the difference between recovering and succumbing to the infection. The findings suggest that doctors should be particularly vigilant when treating patients who are taking olanzapine and also have a history of respiratory disease. It is not that the drug is inherently toxic to the lungs, but rather that it removes a critical layer of protection for those whose lungs are already under siege. This research provides a clear biological explanation for a pattern that doctors have observed for years, highlighting the need for closer monitoring and perhaps different management strategies for this specific group of vulnerable patients.